Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
出版年份 2021 全文链接
标题
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
作者
关键词
-
出版物
Frontiers in Oncology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-10-01
DOI
10.3389/fonc.2021.716751
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
- (2021) Sara Bringhen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
- (2021) Gregorio Barilà et al. Pharmaceuticals
- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2021) M.A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
- (2021) Hareth Nahi et al. AMERICAN JOURNAL OF HEMATOLOGY
- ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)—Optimal dose, updated efficacy and safety results.
- (2021) Roman Hajek et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
- (2021) Cristina Gasparetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).
- (2021) Darrell White et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.
- (2021) Xavier Leleu et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.
- (2021) Thierry Facon et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
- (2021) Weijun Fu et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.
- (2021) Hang Quach et al. JOURNAL OF CLINICAL ONCOLOGY
- Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
- (2021) Anjan Thakurta et al. Oncotarget
- Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
- (2020) Clémentine Boccon‐Gibod et al. BRITISH JOURNAL OF HAEMATOLOGY
- Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
- (2020) Diana Basali et al. BRITISH JOURNAL OF HAEMATOLOGY
- Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
- (2020) Taiga Nishihori et al. Expert Opinion On Drug Safety
- OCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma
- (2020) Fredrik Schjesvold et al. Future Oncology
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
- (2020) Maria Gavriatopoulou et al. LEUKEMIA
- A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma
- (2020) Swetha Kambhampati et al. LEUKEMIA & LYMPHOMA
- Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort
- (2020) Tomas Jelinek et al. HEMATOLOGICAL ONCOLOGY
- Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
- (2020) Jonathan L. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
- (2020) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study
- (2020) Paul G Richardson et al. Lancet Haematology
- Secondary plasma cell leukaemia treated with single agent venetoclax
- (2020) Siobhan V. Glavey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Selinexor, Bortezomib and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series
- (2020) Hila Magen et al. Clinical Lymphoma Myeloma & Leukemia
- Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax
- (2020) Arshia Soleimani et al. Clinical Lymphoma Myeloma & Leukemia
- Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection
- (2020) Panagiotis Malandrakis et al. OncoTargets and Therapy
- Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
- (2020) Robert Cornell et al. AMERICAN JOURNAL OF HEMATOLOGY
- Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma
- (2020) Tarek H. Mouhieddine et al. ANNALS OF HEMATOLOGY
- Melflufen for relapsed and refractory multiple myeloma
- (2020) Albert Oriol et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- CAR T cell therapies for patients with multiple myeloma
- (2020) Lekha Mikkilineni et al. Nature Reviews Clinical Oncology
- Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
- (2020) María-Victoria Mateos et al. Journal of Clinical Medicine
- Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
- (2020) Jonathan L. Kaufman et al. AMERICAN JOURNAL OF HEMATOLOGY
- Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies
- (2019) Alessandro Allegra et al. Clinical Lymphoma Myeloma & Leukemia
- Selinexor: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient
- (2019) Sarolta Bojtine Kovacs et al. HAEMATOLOGICA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients
- (2019) Sarah R Brown et al. BLOOD
- The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- (2019) Taiga Nishihori et al. BLOOD
- The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma
- (2019) Agne Paner et al. BLOOD REVIEWS
- Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)
- (2019) Dawn Swan et al. HAEMATOLOGICA
- The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia
- (2019) Sos Nalghranyan et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2019) Meghan Salcedo et al. Clinical Lymphoma Myeloma & Leukemia
- A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia
- (2019) Allison Kupsh et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma
- (2018) Kian J. Rahbari et al. Clinical Lymphoma Myeloma & Leukemia
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
- (2018) Luciano J. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)
- (2018) Tomas Jelinek et al. AMERICAN JOURNAL OF HEMATOLOGY
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- Venetoclax for the treatment of multiple myeloma
- (2018) Iuliana Vaxman et al. Expert Review of Hematology
- Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
- (2017) Cyrille Touzeau et al. HAEMATOLOGICA
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Melflufen - a peptidase-potentiated alkylating agent in clinical trials
- (2017) Malin Wickström et al. Oncotarget
- Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
- (2017) Cyrille Touzeau et al. HAEMATOLOGICA
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
- (2016) J.-N. Gong et al. BLOOD
- The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
- (2016) Christina Ramsenthaler et al. BMC CANCER
- A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
- (2016) Arghya Ray et al. BRITISH JOURNAL OF HAEMATOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
- (2016) Joel G. Turner et al. Oncotarget
- Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
- (2015) S M Matulis et al. LEUKEMIA
- The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
- (2014) Annamaria Brioli et al. BRITISH JOURNAL OF HAEMATOLOGY
- In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
- (2013) D. Chauhan et al. CLINICAL CANCER RESEARCH
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
- (2012) J Etchin et al. LEUKEMIA
- The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
- (2010) Malin Wickström et al. BIOCHEMICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now